Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy

Phase 3

Completed

Conditions: Gastric Ulcer
Duodenal Ulcer

Interventions: Drug: TAK-438

First Posted Date: 2012-04-02

Last Posted Date: 2014-02-10

Lead Sponsor: Takeda

Target Recruit Count: 27

Registration Number: NCT01568398

Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder

Phase 2

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: vortioxetine (Lu AA21004)
Drug: Placebo
Drug: Duloxetine

First Posted Date: 2012-03-28

Last Posted Date: 2015-02-05

Lead Sponsor: Takeda

Target Recruit Count: 602

Registration Number: NCT01564862

A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 3

Completed

Conditions: Refractory Multiple Myeloma
Relapsed Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Placebo

First Posted Date: 2012-03-28

Last Posted Date: 2023-03-10

Lead Sponsor: Takeda

Target Recruit Count: 722

Registration Number: NCT01564537

Locations: 🇺🇸
University of Arkansas Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Pacific Cancer Medical Center Inc, Anaheim, California, United States
🇺🇸
West Contra Costa Healthcare District, Berkeley, California, United States

and more 21 locations

Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Phase 3

Terminated

Conditions: Glycemic Control

Interventions: Drug: Fasiglifam (TAK-875)
Drug: Placebo
Drug: Sitagliptin

First Posted Date: 2012-03-09

Last Posted Date: 2016-06-02

Lead Sponsor: Takeda

Target Recruit Count: 916

Registration Number: NCT01549964

Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina

Phase 2

Terminated

Conditions: Angina

Interventions: Drug: Febuxostat
Drug: Placebo

First Posted Date: 2012-03-09

Last Posted Date: 2013-12-20

Lead Sponsor: Takeda

Target Recruit Count: 1

Registration Number: NCT01549977

A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer

Phase 3

Completed

Conditions: Premenopausal Breast Cancer

Interventions: Drug: TAP-144-SR(6M)
Drug: TAP-144-SR(3M)

First Posted Date: 2012-03-07

Last Posted Date: 2015-11-26

Lead Sponsor: Takeda

Target Recruit Count: 167

Registration Number: NCT01546649

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: TAP-144-SR(6M)
Drug: TAP-144-SR(3M)

First Posted Date: 2012-03-07

Last Posted Date: 2015-07-21

Lead Sponsor: Takeda

Target Recruit Count: 160

Registration Number: NCT01546623

A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
Biological: TDV New Formulation
Drug: Placebo
Drug: New Formulation Placebo

First Posted Date: 2012-03-02

Last Posted Date: 2019-07-18

Lead Sponsor: Takeda

Target Recruit Count: 140

Registration Number: NCT01542632

Locations: 🇺🇸
Heart Center of the Rockies, Fort Collins, Colorado, United States
🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States
🇺🇸
Advanced Clinical Research, West Jordan, Utah, United States

Study of Combination Therapy With SYR-322

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Alogliptin
Drug: Insulin

First Posted Date: 2012-01-31

Last Posted Date: 2013-11-13

Lead Sponsor: Takeda

Target Recruit Count: 67

Registration Number: NCT01521962

Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years

Phase 2

Completed

Conditions: Healthy

Interventions: Biological: TDV
Biological: Placebo

First Posted Date: 2012-01-18

Last Posted Date: 2023-04-12

Lead Sponsor: Takeda

Target Recruit Count: 360

Registration Number: NCT01511250

Locations: 🇵🇷
University of Puerto Rico School of Medicine, San Juan, Puerto Rico
🇵🇷
Latin Clinical Trial Center, San Juan, Puerto Rico
🇸🇬
National University Hospital, Singapore, Singapore

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy